These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Human Fallopian Tube-Derived Organoids with TP53 and RAD51D Mutations Recapitulate an Early Stage High-Grade Serous Ovarian Cancer Phenotype In Vitro. Dai Y; Xu J; Gong X; Wei J; Gao Y; Chai R; Lu C; Zhao B; Kang Y Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38255960 [TBL] [Abstract][Full Text] [Related]
3. Both fallopian tube and ovarian surface epithelium are cells-of-origin for high-grade serous ovarian carcinoma. Zhang S; Dolgalev I; Zhang T; Ran H; Levine DA; Neel BG Nat Commun; 2019 Nov; 10(1):5367. PubMed ID: 31772167 [TBL] [Abstract][Full Text] [Related]
4. Quantitative analysis of γ-H2AX and p53 nuclear expression levels in ovarian and fallopian tube epithelium from risk-reducing salpingo-oophorectomies in BRCA1 and BRCA2 mutation carriers. Staff S; Tolonen T; Laasanen SL; Mecklin JP; Isola J; Mäenpää J Int J Gynecol Pathol; 2014 May; 33(3):309-16. PubMed ID: 24681744 [TBL] [Abstract][Full Text] [Related]
5. E2F3b over-expression in ovarian carcinomas and in BRCA1 haploinsufficient fallopian tube epithelium. Smith NL; Welcsh P; Press JZ; Agnew KJ; Garcia R; Swisher EM Genes Chromosomes Cancer; 2012 Nov; 51(11):1054-62. PubMed ID: 22887716 [TBL] [Abstract][Full Text] [Related]
6. A putative role for ALDH inhibitors and chemoprevention of BRCA-mutation-driven tumors. McGonigal S; Wu R; Grimley E; Turk EG; Zhai Y; Cho KR; Buckanovich RJ Gynecol Oncol; 2023 Sep; 176():139-146. PubMed ID: 37535994 [TBL] [Abstract][Full Text] [Related]
7. Epigenetic reprogramming of fallopian tube fimbriae in BRCA mutation carriers defines early ovarian cancer evolution. Bartlett TE; Chindera K; McDermott J; Breeze CE; Cooke WR; Jones A; Reisel D; Karegodar ST; Arora R; Beck S; Menon U; Dubeau L; Widschwendter M Nat Commun; 2016 May; 7():11620. PubMed ID: 27216078 [TBL] [Abstract][Full Text] [Related]
8. Proliferation in the normal FTE is a hallmark of the follicular phase, not BRCA mutation status. George SH; Milea A; Shaw PA Clin Cancer Res; 2012 Nov; 18(22):6199-207. PubMed ID: 22967960 [TBL] [Abstract][Full Text] [Related]
9. Premalignant SOX2 overexpression in the fallopian tubes of ovarian cancer patients: Discovery and validation studies. Hellner K; Miranda F; Fotso Chedom D; Herrero-Gonzalez S; Hayden DM; Tearle R; Artibani M; Carrami EM; Williams R; Gaitskell K; Elorbany S; Xu R; Laios A; Buiga P; Ahmed K; Dhar S; Zhang RY; Campo L; Myers KA; Lozano M; Ruiz-Miró M; Gatius S; Mota A; Moreno-Bueno G; Matias-Guiu X; Benítez J; Witty L; McVean G; Leedham S; Tomlinson I; Drmanac R; Cazier JB; Klein R; Dunne K; Bast RC; Kennedy SH; Hassan B; Lise S; Garcia MJ; Peters BA; Yau C; Sauka-Spengler T; Ahmed AA EBioMedicine; 2016 Aug; 10():137-49. PubMed ID: 27492892 [TBL] [Abstract][Full Text] [Related]
10. RANK ligand as a potential target for breast cancer prevention in BRCA1-mutation carriers. Nolan E; Vaillant F; Branstetter D; Pal B; Giner G; Whitehead L; Lok SW; Mann GB; ; Rohrbach K; Huang LY; Soriano R; Smyth GK; Dougall WC; Visvader JE; Lindeman GJ Nat Med; 2016 Aug; 22(8):933-9. PubMed ID: 27322743 [TBL] [Abstract][Full Text] [Related]
14. Microscopic and early-stage ovarian cancers in BRCA1/2 mutation carriers: building a model for early BRCA-associated tumorigenesis. Yates MS; Meyer LA; Deavers MT; Daniels MS; Keeler ER; Mok SC; Gershenson DM; Lu KH Cancer Prev Res (Phila); 2011 Mar; 4(3):463-70. PubMed ID: 21278312 [TBL] [Abstract][Full Text] [Related]
15. Probing the tumorigenic potential of genetic interactions reconstituted in murine fallopian tube organoids. Maru Y; Tanaka N; Tatsumi Y; Nakamura Y; Yao R; Noda T; Itami M; Hippo Y J Pathol; 2021 Oct; 255(2):177-189. PubMed ID: 34184756 [TBL] [Abstract][Full Text] [Related]
16. iPSC-Derived Hereditary Breast Cancer Model Reveals the Portier L; Desterke C; Chaker D; Oudrhiri N; Asgarova A; Dkhissi F; Turhan AG; Bennaceur-Griscelli A; Griscelli F Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33513753 [TBL] [Abstract][Full Text] [Related]
17. PTEN loss in the fallopian tube induces hyperplasia and ovarian tumor formation. Russo A; Czarnecki AA; Dean M; Modi DA; Lantvit DD; Hardy L; Baligod S; Davis DA; Wei JJ; Burdette JE Oncogene; 2018 Apr; 37(15):1976-1990. PubMed ID: 29367766 [TBL] [Abstract][Full Text] [Related]
18. Promoter hypermethylation patterns in fallopian tube epithelium of BRCA1 and BRCA2 germ line mutation carriers. Bijron JG; van der Groep P; van Dorst EB; Seeber LM; Sie-Go DM; Verheijen RH; van Diest PJ Endocr Relat Cancer; 2012 Feb; 19(1):69-81. PubMed ID: 22143498 [TBL] [Abstract][Full Text] [Related]
19. [Oncopathological aspects of BRCA1 and BRCA2 genes inactivation in tumors of ovary, fallopian tube and pelvic peritoneum]. Škapa P; Dundr P Cesk Patol; 2016; 52(4):199-204. PubMed ID: 27869446 [TBL] [Abstract][Full Text] [Related]
20. Identification of a preneoplastic gene expression profile in tubal epithelium of BRCA1 mutation carriers. Press JZ; Wurz K; Norquist BM; Lee MK; Pennil C; Garcia R; Welcsh P; Goff BA; Swisher EM Neoplasia; 2010 Dec; 12(12):993-1002. PubMed ID: 21170264 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]